Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
CGDV vs IBB: how they differ
CGDV and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
Capital Group Dividend Value ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, CGDV and IBB hold 0% of their money in the same securities at the same weight.
| Only in CGDV | Only in IBB |
|---|---|
| Microsoft Corp 5.81% | VERTEX PHARMACEUTICALS 7.94% |
| NVIDIA Corp 5.66% | AMGEN INC 7.85% |
| Broadcom Inc 5.16% | GILEAD SCIENCES 7.44% |
| Alphabet Inc 3.60% | REGENERON PHARMACEUTICALS 5.92% |
| Meta Platforms Inc 3.33% | ARGENX SE ADR 3.78% |
| Eli Lilly & Co 3.15% | MODERNA 3.67% |
| Applied Materials Inc 3.12% | NATERA 3.30% |
| General Electric Co 3.08% | REVOLUTION MEDICINES 2.87% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated May 31, 2026 and Sep 10, 2026.
| CGDV Capital Group Dividend Value ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Capital Group | iShares |
| What it is | Dividend Value | Biotechnology |
| Total return, 1 year | +18.7% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +1.2 pts | +24.0 pts |
| Expense ratio | 0.33% | 0.44% |
| Already in the S&P 500 | 91.0% | 35.6% |
| Holdings | 53 | 233 |
CGDV in plain words
CGDV is an index equity fund tracking the Dividend Value. Over the year to Sep 11, 2026 it returned +18.7% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.33% a year. By its holdings filed for May 31, 2026, 91% of the fund by weight is stocks the S&P 500 also holds, across 53 positions, with the top ten at 38.8%. It sat 4.0% below its high of Aug 13, 2026 on Sep 11, 2026.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Sep 10, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 233 positions, with the top ten at 47.5%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, CGDV or IBB?
- In the year to Sep 13, 2026, with distributions reinvested, CGDV returned +18.7% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, CGDV or IBB?
- CGDV charges 0.33% a year and IBB charges 0.44%, so CGDV is cheaper. Fees come from each fund's prospectus.
- How much do CGDV and IBB overlap with the S&P 500?
- By their latest filed holdings, 91% of CGDV and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, CGDV against IBB, data as of Sep 13, 2026. https://etfiq.com/compare/any/cgdv-vs-ibb Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources